Protein m fusion proteins and uses
OwnerJay Dela Cruzinventor
Life of this patent
Estimating the term…
Abstract
Fusion proteins with immunoglobulin binding properties, their uses and related methods and compositions are disclosed. The fusion proteins are comprised of an antibody-binding fragment of protein M from Mycoplasma spp. conjugated to a receptor fragment. The receptor fragment is a protein fragment to which a pathogen or a toxin can specifically bind. The fusion proteins can be used to neutralize or eradicate a wide group of pathogens or toxins.
Claims16
A method for neutralizing a pathogen, wherein the pathogen has a specific binding affinity for a receptor fragment, the method comprising:
- providing conditions for interaction between the pathogen and a fusion protein that comprises a polypeptide having at least 90% identity over its entire length with either the sequence set forth in SEQ ID NO:
- 1 or the sequence set forth in SEQ ID NO:
- 2 conjugated to the receptor fragment, whereby the fusion protein binds to and neutralizes the pathogen.
A method for eradicating a bloodborne pathogen in a subject, wherein the pathogen has a specific binding affinity for a receptor fragment inside a body of the subject, the method comprising:
- receiving a sample of blood, serum or plasma from the subject or from a donor compatible with the subject, wherein the sample comprises immunoglobulins;
- adding a fusion protein that comprises a polypeptide having at least 90% identity over its entire length with either the sequence set forth in SEQ ID NO:
- 1 or the sequence set forth in SEQ ID NO:
- 2 conjugated to the receptor fragment to the sample, wherein the fusion protein binds to the immunoglobulins present in the sample;
- administrating the sample having the fusion protein bound to the immunoglobulins into the subject's body, in an amount sufficient to eradicate the pathogen in the subject.
A fusion protein having a specific binding affinity for an immunoglobulin molecule, comprising a polypeptide having at least 90% identity over its entire length with either the sequence set forth in SEQ ID NO:
- 1 or the sequence set forth in SEQ ID NO:
- 2, wherein the polypeptide is conjugated to a fusion partner,—having a sequence that is at least 90% identical to one of the following sequences:
- SEQ ID NO:
- 15-36.
A method for neutralizing a toxin in a subject, wherein the toxin has a specific binding affinity for a receptor fragment, the method comprising:
- receiving a sample of blood, serum or plasma from the subject or from a donor compatible with the subject, wherein the sample comprises immunoglobulins;
- adding a conjugated protein that comprises a polypeptide having at least 90% identity over its entire length with either the sequence set forth in SEQ ID NO:
- 1 or the sequence set forth in SEQ ID NO:
- 2 conjugated to the receptor fragment to the sample, wherein the conjugated protein binds to the immunoglobulins present in the sample;
- administrating the sample having the conjugated protein bound to the immunoglobulins into the subject's body, in an amount sufficient to eradicate the toxin in the subject.
Dependencies are inferred from the claim text.